The UK lung cancer screening trial: A pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer

Health Technology Assessment

Volumn 20, Issue 40, 2016, Pages 1-146

  Field, John K ^a   Duffy, Stephen W ^b   Baldwin, David R ^c   Brain, Kate E ^d   Devaraj, Anand ^e   Eisen, Tim ^f   Green, Beverley A ^a   Holemans, John A ^g   Kavanagh, Terry ^h   Kerr, Keith M ⁱ   Ledson, Martin ^g   Lifford, Kate J ^d   McRonald, Fiona E ^a   Nair, Arjun ^j   Page, Richard D ^g   Parmar, Mahesh K B ^k   Rintoul, Robert C ^l   Screaton, Nicholas ^l   Wald, Nicholas J ^b   Weller, David ^m   Whynes, David K ⁿ   Williamson, Paula R ^a   Yadegarfar, Ghasem ^a   Hansell, David M ^e   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^h Lung Cancer Patient Advocate   (United Kingdom)

ⁱ ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^j GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l PAPWORTH HOSPITAL   (United Kingdom)

^m UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁿ UNIVERSITY OF NOTTINGHAM   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ANXIETY; ARTICLE; CANCER DISTRESS; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION SATISFACTION; DEPRESSION; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; EDUCATIONAL STATUS; ETHNICITY; FEMALE; FOLLOW UP; GENERAL HOSPITAL; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; LOW DOSE COMPUTER ASSISTED TOMOGRAPHY; LOWEST INCOME GROUP; LUNG CANCER; LUNG FUNCTION; LUNG NODULE; MALE; MARRIAGE; MEDICAL EDUCATION; MEDICAL PERSONNEL; MULTIDISCIPLINARY TEAM; OUTCOME ASSESSMENT; PILOT STUDY; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY CONTROL; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL; READING; REPEAT PROCEDURE; SMOKING; SOCIAL PSYCHOLOGY; SPIROMETRY; TUMOR VOLUME; UNITED KINGDOM; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; PSYCHOLOGY; QUALITY ADJUSTED LIFE YEAR; RADIATION DOSE; RISK FACTOR; SOCIOECONOMICS; X-RAY COMPUTED TOMOGRAPHY;

AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; QUALITY-ADJUSTED LIFE YEARS; RADIATION DOSAGE; RISK FACTORS; SOCIOECONOMIC FACTORS; TOMOGRAPHY, X-RAY COMPUTED; UNITED KINGDOM;

EID: 84970024824     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta20400     Document Type: Article

References (149)

1. Cancer Research UK. Cancer Statistics for the UK. 2012. URL: www.cancerresearchuk.org/health-professional/cancer-statistics (accessed May 2016).
2. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602. http://dx.doi.org/10.1097/JTO.0b013e31807a2f81
3. National Cancer Research Institute. Lung Cancer UK Price Tag Eclipses the Cost of Any Other Cancer. 2012. URL: www.cancerresearchuk.org/about-us/cancer-news/press-release/lung-cancer-uk-price-tag-eclipses-the-cost-of-any-other-cancer (accessed June 2012).
4. Parkin DM. 2. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer 2011;105 (Suppl. 2):6-13. http://dx.doi.org/10.1038/bjc.2011.475
5. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst 2011;103:1827-39. http://dx.doi.org/10.1093/jnci/djr483
6. Cote ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer 2012;48:1957-68. http://dx.doi.org/10.1016/j.ejca.2012.01.038
7. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLOS ONE 2011;6:e17479. http://dx.doi.org/10.1371/journal.pone.0017479
8. Brenner DR, Boffetta P, Duell EJ, Bickeboller H, Rosenberger A, McCormack V, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol 2012;176:573-85. http://dx.doi.org/10.1093/aje/kws151
9. Shack L, Jordan C, Thomson CS, Mak V, Moller H. Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer 2008;8:271. http://dx.doi.org/10.1186/1471-2407-8-271
10. Forman D. Cancer Incidence by Deprivation England, 1995-2004. London: National Cancer Intelligence Network; 2008.
11. Rowan S. Trends in cancer incidence by deprivation, England and Wales, 1990-2002. Health Stat Q 2007;36:24-35.
12. Raaschou-Nielsen O, Andersen ZJ, Beelen R, Samoli E, Stafoggia M, Weinmayr G, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 2013;14:813-22. http://dx.doi.org/10.1016/S1470-2045(13)70279-1
13. Field JK, Chen Y, Marcus MW, McRonald FE, Raji OY, Duffy SW. The contribution of risk prediction models to early detection of lung cancer. J Surg Oncol 2013;108:304-11. http://dx.doi.org/10.1002/jso.23384
14. Van Klaveren RJ, de Koning HJ, Mulshine J, Hirsch FR. Lung cancer screening by spiral CT. What is the optimal target population for screening trials? Lung Cancer 2002;38:243-52. http://dx.doi.org/10.1016/S0169-5002(02)00222-2
15. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-8. http://dx.doi.org/10.1093/jnci/95.6.470
16. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) 2008;1:250-4. http://dx.doi.org/10.1158/1940-6207.CAPR-08-0060
17. Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728-36. http://dx.doi.org/10.1056/NEJMoa1211776
18. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-54. http://dx.doi.org/10.1056/NEJMoa1301851
19. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26. http://dx.doi.org/10.1093/jnci/djk153
20. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98:270-6. http://dx.doi.org/10.1038/sj.bjc.6604158
21. Cassidy A, Myles JP, Liloglou T, Duffy SW, Field JK. Defining high-risk individuals in a population-based molecular-epidemiological study of lung cancer. Int J Oncol 2006;28:1295-301. http://dx.doi.org/10.3892/ijo.28.5.1295
22. Garcia-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). Cancer Causes Control 1997;8:544-53. http://dx.doi.org/10.1023/A:1018481910663
23. Raji OY, Duffy SW, Agbaje OF, Baker SG, Christiani DC, Cassidy A, et al. Predictive accuracy of the Liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med 2012;157:242-50. http://dx.doi.org/10.7326/0003-4819-157-4-201208210-00004
24. Peres J. Lung cancer screening gets risk-specific. J Natl Cancer Inst 2013;105:1-2. http://dx.doi.org/10.1093/jnci/djs631
25. Field JK, Duffy SW. Lung cancer screening: the way forward. Br J Cancer 2008;99:557-62. http://dx.doi.org/10.1038/sj.bjc.6604509
26. Brett GZ. Earlier diagnosis and survival in lung cancer. Br Med J 1969;4:260-2. http://dx.doi.org/10.1136/bmj.4.5678.260
27. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011;306:1865-73. http://dx.doi.org/10.1001/jama.2011.1591
28. Khan AF. Overview of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. National Cancer Institute; 2012. URL: http://benchmarks.cancer.gov/2012/05/overview-of-the-prostate-lung-colorectal-and-ovarian-plco-cancer-screening-trial/ (accessed June 2012).
29. Reeves AP, Kostis WJ. Computer-aided diagnosis for lung cancer. Radiol Clin North Am 2000;38:497-509. http://dx.doi.org/10.1016/S0033-8389(05)70180-9
30. Yankelevitz DF, Reeves AP, Kostis WJ, Zhao B, Henschke CI. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology 2000;217:251-6. http://dx.doi.org/10.1148/radiology.217.1.r00oc33251
31. Swensen SJ, Viggiano RW, Midthun DE, Muller NL, Sherrick A, Yamashita K, et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000;214:73-80. http://dx.doi.org/10.1148/radiology.214.1.r00ja1473
32. Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593-7. http://dx.doi.org/10.1016/S0140-6736(03)14188-8
33. Sone S, Takashima S, Li F, Yang Z, Honda T, Maruyama Y, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998;351:1242-5. http://dx.doi.org/10.1016/S0140-6736(97)08229-9
34. Field JK, Smith RA, Duffy SW, Berg CD, van Klaveren R, Henschke CI, et al. The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. J Thorac Oncol 2006;1:497-8. http://dx.doi.org/10.1016/S1556-0864(15)31618-X
35. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 2013;369:920-31. http://dx.doi.org/10.1056/NEJMoa1208962
36. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
37. Van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221-9. http://dx.doi.org/10.1056/NEJMoa0906085
38. Pastorino U. Early detection of lung cancer. Respiration 2006;73:5-13. http://dx.doi.org/10.1159/000090990
39. Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21:308-15. http://dx.doi.org/10.1097/CEJ.0b013e328351e1b6
40. Picozzi G, Paci E, Lopez Pegna A, Bartolucci M, Roselli G, De Francisci A, et al. Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ‘Italung-CT’. Radiol Med 2005;109:17-26.
41. Lopes Pegna A, Picozzi G, Mascalchi M, Carozzi FM, Carrozzi L, Comin C, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer 2009;64:34-40. http://dx.doi.org/10.1016/j.lungcan.2008.07.003
42. Infante M, Lutman FR, Cavuto S, Brambilla G, Chiesa G, Passera E, et al. Lung cancer screening with spiral CT baseline results of the randomized DANTE trial. Lung Cancer 2008;59:355-63. http://dx.doi.org/10.1016/j.lungcan.2007.08.040
43. Blanchon T, Brechot JM, Grenier PA, Ferretti GR, Lemarie E, Milleron B, et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer 2007;58:50-8. http://dx.doi.org/10.1016/j.lungcan.2007.05.009
44. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax 2012;67:296-301. http://dx.doi.org/10.1136/thoraxjnl-2011-200736
45. Pedersen J, Ashraf H, Dirksen A, Bach K, Hansen H, Thoennesen P, et al. The Danish randomized lung cancer CT screening trial: overall design and results of the prevalence round. J Thorac Oncol 2009;5:608-14. http://dx.doi.org/10.1097/JTO.0b013e3181a0d98f
46. Field JK, Hansell DM, Duffy SW, Baldwin DR. CT screening for lung cancer: countdown to implementation. Lancet Oncol 2013;14:e591-600. http://dx.doi.org/10.1016/S1470-2045(13)70293-6
47. Field JK, van Klaveren R, Pedersen JH, Pastorino U, Paci E, Becker N, et al. European randomized lung cancer screening trials: post NLST. J Surg Oncol 2013;108:280-6. http://dx.doi.org/10.1002/jso.23383
48. Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet 2013;382:732-41. http://dx.doi.org/10.1016/S0140-6736(13)61614-1
49. Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, et al. The National Lung Screening Trial: overview and study design. Radiology 2011;258:243-53. http://dx.doi.org/10.1148/radiol.10091808
50. UK National Screening Committee. Criteria for Appraising the Viability, Effectiveness and Appropriateness of a Screening Programme. 2014. London: Public Health England. URL: www.screening.nhs.uk/criteria (accessed November 2014).
51. Black C, de Verteuil R, Walker S, Ayres J, Boland A, Bagust A, et al. Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. Thorax 2007;62:131-8. http://dx.doi.org/10.1136/thx.2006.064659
52. Whynes DK. Could CT screening for lung cancer ever be cost effective in the United Kingdom? Cost Eff Resour Alloc 2008;6:5. http://dx.doi.org/10.1186/1478-7547-6-5
53. Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011;66:308-13. http://dx.doi.org/10.1136/thx.2010.152066
54. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-33. http://dx.doi.org/10.1016/S0140-6736(10)60551-X
55. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, et al. The multicentre aneurysm screening study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002;360:1531-9. http://dx.doi.org/10.1016/S0140-6736(02)11522-4
56. Jakes RW, Duffy SW, Ng FC, Gao F, Ng EH. Mammographic parenchymal patterns and risk of breast cancer at and after a prevalence screen in Singaporean women. Int J Epidemiol 2000;29:11-19. http://dx.doi.org/10.1093/ije/29.1.11
57. UK Lung Cancer Screening Trial. Background to UKLS. URL: www.ukls.org (accessed November 2014).
58. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70. http://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x
59. Lerman C, Daly M, Sands C, Balshem A, Lustbader E, Heggan T, et al. Mammography adherence and psychological distress among women at risk for breast cancer. J Natl Cancer Inst 1993;85:1074-80. http://dx.doi.org/10.1093/jnci/85.13.1074
60. Watson M, Lloyd S, Davidson J, Meyer L, Eeles R, Ebbs S, et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer 1999;79:868-74. http://dx.doi.org/10.1038/sj.bjc.6690139
61. Field J. HTA Protocol. URL: www.hta.ac.uk/project/2382.asp (accessed June 2012).
62. Department for Communities and Local Government. English Indices of Deprivation 2010. London: Department for Communities and Local Government; 2011.
63. Senn S. Statistical Issues in Drug Development. 2nd edn. Hoboken, NJ: Wiley; 2007. http://dx.doi.org/10.1002/9780470723586
64. Clayton D, Hills M. Statistical Models in Epidemiology. 1st edn. Oxford: Oxford University Press; 1993.
65. Collett D. Modelling Survival Data in Medical Research. 1st edn. London: Chapman and Hall; 2003.
66. Robinson SH, Harris H. Smoking and Drinking Among Adults, 2009. A Report on the 2009 General Lifestyle Survey. London: Office for National Statistics; 2009.
67. Nat Cen Social Research, Royal Free and University College Medical School, Department of Epidemiology and Public Health. Health Survey for England, 2010. 3rd edn. Colchester: UK Data Archive; 2015.
68. Wardle J, Sutton S, Williamson S, Taylor T, McCaffery K, Cuzick J, et al. Psychosocial influences on older adults’ interest in participating in bowel cancer screening. Prev Med 2000;31:323-34. http://dx.doi.org/10.1006/pmed.2000.0725
69. Espinosa de Los Monteros K, Gallo LC. The relevance of fatalism in the study of Latinas’ cancer screening behavior: a systematic review of the literature. Int J Behav Med 2011;18:310-18. http://dx.doi.org/10.1007/s12529-010-9119-4
70. Miles A, Rainbow S, von Wagner C. Cancer fatalism and poor self-rated health mediate the association between socioeconomic status and uptake of colorectal cancer screening in England. Cancer Epidemiol Biomarkers Prev 2011;20:2132-40. http://dx.doi.org/10.1158/1055-9965.EPI-11-0453
71. Marten K, Seyfarth T, Auer F, Wiener E, Grillhosl A, Obenauer S, et al. Computer-assisted detection of pulmonary nodules: performance evaluation of an expert knowledge-based detection system in consensus reading with experienced and inexperienced chest radiologists. Eur Radiol 2004;14:1930-8. http://dx.doi.org/10.1007/s00330-004-2389-y
72. Brochu B, Beigelman-Aubry C, Goldmard JL, Raffy P, Grenier PA, Lucidarme O. [Computer-aided detection of lung nodules on thin collimation MDCT: impact on radiologists’ performance.] J Radiol 2007;88:573-8. http://dx.doi.org/10.1016/S0221-0363(07)89857-X
73. Rubin GD, Lyo JK, Paik DS, Sherbondy AJ, Chow LC, Leung AN, et al. Pulmonary nodules on multi-detector row CT scans: performance comparison of radiologists and computer-aided detection. Radiology 2005;234:274-83. http://dx.doi.org/10.1148/radiol.2341040589
74. Roos JE, Paik D, Olsen D, Liu EG, Chow LC, Leung AN, et al. Computer-aided detection (CAD) of lung nodules in CT scans: radiologist performance and reading time with incremental CAD assistance. Eur Radiol 2010;20:549-57. http://dx.doi.org/10.1007/s00330-009-1596-y
75. Wormanns D, Ludwig K, Beyer F, Heindel W, Diederich S. Detection of pulmonary nodules at multirow-detector CT: effectiveness of double reading to improve sensitivity at standard-dose and low-dose chest CT. Eur Radiol 2005;15:14-22. http://dx.doi.org/10.1007/s00330-004-2527-6
76. Beigelman-Aubry C, Raffy P, Yang W, Castellino RA, Grenier PA. Computer-aided detection of solid lung nodules on follow-up MDCT screening: evaluation of detection, tracking, and reading time. AJR Am J Roentgenol 2007;189:948-55. http://dx.doi.org/10.2214/AJR.07.2302
77. Fraioli F, Bertoletti L, Napoli A, Calabrese FA, Masciangelo R, Cortesi E, et al. [Volumetric evaluation of therapy response in patients with lung metastases. Preliminary results with a computer system (CAD) and comparison with unidimensional measurements]. Radiol Med 2006;111:365-75. http://dx.doi.org/10.1007/s11547-006-0035-2
78. Li Q. Recent progress in computer-aided diagnosis of lung nodules on thin-section CT. Comput Med Imaging Graph 2007;31:248-57. http://dx.doi.org/10.1016/j.compmedimag.2007.02.005
79. Henschke CI, Yip R, Yankelevitz DF, Smith JP. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2013;158:246-52. http://dx.doi.org/10.7326/0003-4819-158-4-201302190-00004
80. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013;369:910-19. http://dx.doi.org/10.1056/NEJMoa1214726
81. Nair A, Baldwin DR, Field JK, Hansell DM, Devaraj A. Measurement methods and algorithms for the management of solid nodules. J Thorac Imaging 2012;27:230-9. http://dx.doi.org/10.1097/RTI.0b013e31824f83e1
82. Goo JM. A computer-aided diagnosis for evaluating lung nodules on chest CT: the current status and perspective. Korean J Radiol 2011;12:145-55. http://dx.doi.org/10.3348/kjr.2011.12.2.145
83. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG 2004;111:1437-43. http://dx.doi.org/10.1111/j.1471-0528.2004.00279.x
84. Brett J, Bankhead C, Henderson B, Watson E, Austoker J. The psychological impact of mammographic screening. A systematic review. Psychooncology 2005;14:917-38. http://dx.doi.org/10.1002/pon.904
85. Aggestrup LM, Hestbech MS, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences of allocation to lung cancer screening: a randomised controlled trial. BMJ Open 2012;2:e000663. http://dx.doi.org/10.1136/bmjopen-2011-000663
86. Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. Med Decis Making 2008;28:917-25. http://dx.doi.org/10.1177/0272989X08322013
87. Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst 2004;96:1083-94. http://dx.doi.org/10.1093/jnci/djh194
88. Van den Bergh KA, Essink-Bot ML, Borsboom GJ, Scholten ET, van Klaveren RJ, de Koning HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J 2011;38:154-61. http://dx.doi.org/10.1183/09031936.00123410
89. Van den Bergh KA, Essink-Bot ML, Borsboom GJ, Th Scholten E, Prokop M, de Koning HJ, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer 2010;102:27-34. http://dx.doi.org/10.1038/sj.bjc.6605459
90. Van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax 2010;65:600-5. http://dx.doi.org/10.1136/thx.2009.133751
91. Van der Aalst CM, van Klaveren RJ, van den Bergh KA, Willemsen MC, de Koning HJ. The impact of a lung cancer computed tomography screening result on smoking abstinence. Eur Respir J 2011;37:1466-73. http://dx.doi.org/10.1183/09031936.00035410
92. Silvestri GA, Nietert PJ, Zoller J, Carter C, Bradford D. Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax 2007;62:126-30. http://dx.doi.org/10.1136/thx.2005.056036
93. Van den Bergh KA, Essink-Bot ML, van Klaveren RJ, de Koning HJ. Informed participation in a randomised controlled trial of computed tomography screening for lung cancer. Eur Respir J 2009;34:711-20. http://dx.doi.org/10.1183/09031936.00098908
94. McRonald FE, Yadegarfar G, Baldwin DR, Devaraj A, Brain KE, Eisen T, et al. The UK Lung Screen (UKLS): demographic profile of first 88897 approaches provides recommendations for population screening. Cancer Prev Res (Phila) 2014;7:362-71. http://dx.doi.org/10.1158/1940-6207.CAPR-13-0206
95. Jonnalagadda S, Bergamo C, Lin JJ, Lurslurchachai L, Diefenbach M, Smith C, et al. Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer 2012;77:526-31. http://dx.doi.org/10.1016/j.lungcan.2012.05.095
96. Patel D, Akporobaro A, Chinyanganya N, Hackshaw A, Seale C, Spiro SG, et al. Attitudes to participation in a lung cancer screening trial: a qualitative study. Thorax 2012;67:418-25. http://dx.doi.org/10.1136/thoraxjnl-2011-200055
97. Brain K, Parsons E, Bennett P, Cannings-John R, Hood K. The evolution of worry after breast cancer risk assessment: 6-year follow-up of the TRACE study cohort. Psychooncology 2011;20:984-91.
98. Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert ML, et al. Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Making 1996;16:58-64. http://dx.doi.org/10.1177/0272989X9601600114
99. Clements A, Henderson BJ, Tyndel S, Evans G, Brain K, Austoker J, et al. Diagnosed with breast cancer while on a family history screening programme: an exploratory qualitative study. Eur J Cancer Care (Engl) 2008;17:245-52. http://dx.doi.org/10.1111/j.1365-2354.2007.00837.x
100. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-6. http://dx.doi.org/10.1001/jama.291.22.2720
101. Von Wagner C. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol 2011;40:712-8. http://dx.doi.org/10.1093/ije/dyr008
102. Ironmonger L, Ohuma E, Ormiston-Smith N, Gildea C, Thomson CS, Peake MD. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. Br J Cancer 2015;112:207-16. http://dx.doi.org/10.1038/bjc.2014.596
103. Whynes DK. Economics of cancer screening programmes. Expert Rev Pharmacoecon Outcomes Res 2004;4:61-9. http://dx.doi.org/10.1586/14737167.4.1.61
104. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: NICE; 2008.
105. Whynes DK, on behalf of the Nottingham FOB Screening Trial. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial. J Med Screen 2004;11:11-15. http://dx.doi.org/10.1258/096914104772950691
106. Whynes DK, Mangham CM, Balfour TW, Scholefield JH. Analysis of deaths occurring within the Nottingham trial of faecal occult blood screening for colorectal cancer. Gut 2010;59:1088-93. http://dx.doi.org/10.1136/gut.2009.192971
107. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2013;159:411-20. http://dx.doi.org/10.7326/0003-4819-159-6-201309170-00690
108. Kucharczyk MJ, Menezes RJ, McGregor A, Paul NS, Roberts HC. Assessing the impact of incidental findings in a lung cancer screening study by using low-dose computed tomography. Can Assoc Radiol J 2011;62:141-5. http://dx.doi.org/10.1016/j.carj.2010.02.008
109. Priola AM, Priola SM, Giaj-Levra M, Basso E, Veltri A, Fava C, et al. Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using low-dose spiral computed tomography. Clin Lung Cancer 2013;14:139-48. http://dx.doi.org/10.1016/j.cllc.2012.05.005
110. Department of Health. Reference Costs 2011-12. 2012. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/213060/2011-12-reference-costs-publication.pdf (accessed May 2016).
111. National Collaborating Centre for Cancer (NCCC). The Diagnosis and Treatment of Lung Cancer (Update of NICE Clinical Guideline 24). Cardiff: NCCC; 2011.
112. Whyte S, Chilcott J, Cooper K, Essat M, Stevens J, Wong R, et al. Re-appraisal of the Options for Colorectal Cancer Screening: Report for the NHS Bowel Cancer Screening Programme. Sheffield: School of Health and Related Research; 2011.
113. De Haan MC, Thomeer M, Stoker J, Dekker E, Kuipers EJ, van Ballegooijen M. Unit costs in population-based colorectal cancer screening using CT colonography performed in university hospitals in The Netherlands. Eur Radiol 2013;23:897-907. http://dx.doi.org/10.1007/s00330-012-2689-6
114. Logan RFA, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C, et al. Outcomes of the bowel cancer screening programme (BCSP) in England after the first 1 million tests. Gut 2012;61:1439-46. http://dx.doi.org/10.1136/gutjnl-2011-300843
115. International Early Lung Cancer Action Program Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med 2006;355:1763-71. http://dx.doi.org/10.1056/NEJMoa060476
116. Nawa T, Nakagawa T, Mizoue T, Kusano S, Chonan T, Fukai S, et al. Long-term prognosis of patients with lung cancer detected on low-dose chest computed tomography screening. Lung Cancer 2012;75:197-202. http://dx.doi.org/10.1016/j.lungcan.2011.07.002
117. Sone S, Nakayama T, Honda T, Tsushima K, Li F, Haniuda M, et al. Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. Lung Cancer 2007;58:329-41. http://dx.doi.org/10.1016/j.lungcan.2007.06.022
118. Bach PB, Jett JR, Pastroino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA 2007;297:953-61. http://dx.doi.org/10.1001/jama.297.9.953
119. Cerfolio RJ, Bryant AS. Survival of patients with true pathologic stage 1 non-small cell lung cancer. Ann Thorac Surg 2009;88:917-23. http://dx.doi.org/10.1016/j.athoracsur.2009.05.040
120. Hung JJ, Jeng WJ, Hsu WH, Huang BS, Wu YC. Time trends of overall survival and survival after recurrence in completely resected stage I non-small cell lung cancer. J Thorac Oncol 2012;7:397-405. http://dx.doi.org/10.1097/JTO.0b013e31823b564a
121. Provencio M, Isla D, Sánchez A, Cantos B. Inoperable stage III non-small cell lung cancer: current treatment and role of vinorelbine. J Thorac Dis 2011;3:197-204.
122. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-94.
123. Ternel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-42. http://dx.doi.org/10.1056/NEJMoa1000678
124. Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 2013;68:551-64. http://dx.doi.org/10.1136/thoraxjnl-2012-202297
125. Solomon T, Rachet B, Whitehead S, Coleman MP. Cancer Survival in England: Patients Diagnosed 2007-2011 and Followed up to 2012. London: Office for National Statistics; 2013.
126. Goldberg SW, Mulshine JL, Hagstrom D, Pyenson BS. An actuarial approach to comparing early stage and late stage lung cancer mortality and survival. Popul Health Manag 2010;13:33-46. http://dx.doi.org/10.1089/pop.2009.0010
127. Wu D, Erwin D, Rosner GL. Sojourn time and lead time projection in lung cancer screening. Lung Cancer 2011;72:322-6. http://dx.doi.org/10.1016/j.lungcan.2010.10.010
128. Shmueli A, Fraifeld S, Peretz T, Gutfeld O, Gips M, Sosna J, et al. Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience. Value Health 2013;16:922-31. http://dx.doi.org/10.1016/j.jval.2013.05.007
129. Soda H, Oka M, Tomita H, Nagashima S, Soda M, Kohno S. Length and lead time biases in radiologic screening for lung cancer. Respiration 1999;66:511-17. http://dx.doi.org/10.1159/000029450
130. Henschke CI, Yankelevitz DF, Kostis WJ. CT screening for lung cancer. Semin Ultrasound CT MRI 2003;24:23-32. http://dx.doi.org/10.1016/S0887-2171(03)90022-9
131. Patz EF, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA 2014;174:269-74. http://dx.doi.org/10.1001/jamainternmed.2013.12738
132. McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology 2008;248:278-87. http://dx.doi.org/10.1148/radiol.2481071446
133. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005;235:259-65. http://dx.doi.org/10.1148/radiol.2351041662
134. McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, et al. Adopting helical CT screening for lung cancer. Cancer 2008;113:3440-9. http://dx.doi.org/10.1002/cncr.23962
135. De Koning HJ, Meza R, Plevritis SK, Ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014;160:311-20. http://dx.doi.org/10.7326/M13-2316
136. National Lung Cancer Audit Project Team. National Lung Cancer Audit Report 2013. Leeds: Health and Social Care Information Centre; 2013.
137. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D (Discussion Paper 172). York: Centre for Health Economics, University of York; 1999.
138. Black C, Bagust A, Boland A, Walker S, McLeod C, De Verteuil R, et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess 2006;10(3). http://dx.doi.org/10.3310/hta10030
139. McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano L, Tramontano AC, et al. Cost-effectiveness of CT screening for lung cancer in the US. J Thorac Oncol 2011;6:1841-8. http://dx.doi.org/10.1097/JTO.0b013e31822e59b3
140. Pyenson BS, Sander MS, Jiang Y, Kahn H, Mulshine JL. An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. Health Aff (Millwood) 2012;31:770-9. http://dx.doi.org/10.1377/hlthaff.2011.0814
141. Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLOS ONE 2013;8:e71379. http://dx.doi.org/10.1371/journal.pone.0071379
142. Cipriano LE, Romanus D, Earle CC, Neville BA, Halpern EF, Gazelle GS, et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health 2011;14:41-52. http://dx.doi.org/10.1016/j.jval.2010.10.006
143. D’Amelio AM Jr, Cassidy A, Asomaning K, Raji OY, Duffy SW, Field JK, et al. Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer 2010;103:423-9. http://dx.doi.org/10.1038/sj.bjc.6605759
144. Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 2014;371:1793-802. http://dx.doi.org/10.1056/NEJMoa1312547
145. Callister MEJ, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J et al. British Society Guidelines for the investigation and management of pulmonary nodules. On behalf of the BTS Standards of Care Committe. Thorax 2015;70(Suppl. 2):ii1-54. http://dx.doi.org/10.1136/thoraxjnl-2015-207168
146. National Institute for Health and Care Excellence. The Diagnosis and Treatment of Lung Cancer (Update). NICE Clinical Guidelines. Cardiff: National Collaborating Centre for Cancer; 2011.
147. Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C, et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010;65 (Suppl. 3):1-27. http://dx.doi.org/10.1136/thx.2010.145938
148. Duffy SW, Field JK, Allgood PC, Seigneurin A. Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. Br J Cancer 2014;110:1834-40. http://dx.doi.org/10.1038/bjc.2014.63
149. Iyen-Omofoman B, Tata LJ, Baldwin DR, Smith CJ, Hubbard RB. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier. Thorax 2013;68:451-9. http://dx.doi.org/10.1136/thoraxjnl-2012-202348